Press Release

Rubius Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

July 23, 2018

CAMBRIDGE, Mass., July 23, 2018 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a biotechnology company pioneering the development of a new class of ready-to-use cellular therapies, today announced the closing of its initial public offering of 12,055,450 shares of common stock at a public offering price of $23.00 per share. The gross proceeds from the offering were $277.3 million before deducting underwriting discounts and commissions and estimated offering expenses. This includes the exercise in full by the underwriters of their option to purchase up to 1,572,450 additional shares of common stock from the Company at the public offering price, less underwriting discounts and commissions. All of the shares in the offering were offered by Rubius Therapeutics. The shares commenced trading on The Nasdaq Global Select Market on July 18, 2018, under the ticker symbol “RUBY.”

J.P. Morgan, Morgan Stanley, Jefferies and Leerink Partners acted as joint book-running managers for the offering. 

The offering was made only by means of a prospectus. Copies of the final prospectus may be obtained from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, telephone: (866) 803-9204, or by emailing; Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014; Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by telephone at (877) 547-6340, or by email at; or Leerink Partners LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA, 02110, by telephone at (800) 808-7525, ext. 6132, or by email at

Registration statements relating to the shares being sold in this offering have been filed with the Securities and Exchange Commission and became effective on July 17, 2018. Copies of the registration statements can be accessed through the SEC’s website at This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Rubius Therapeutics
Rubius Therapeutics is pioneering the development of a new class of medicines, Red Cell Therapeutics, or RCTs. Rubius has designed a proprietary platform to genetically engineer and culture RCTs that are selective, potent and ready-to-use cellular therapies.

Media Contact:
Dan Budwick
1AB, Inc.
+1 (973) 271-6085

Investor Contact:
Lori Melançon
Vice President, Corporate Communications and Investor Relations
+1 (617) 949-5296


Primary Logo


Source: Rubius Therapeutics